Praxis Precision Medicines, Inc.

$335.61+4.68%(+$15.00)
TickerSpark Score
56/100
Mixed
67
Valuation
20
Profitability
10
Growth
84
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRAX research report →

52-Week Range93% of range
Low $35.21
Current $335.61
High $358.76

Companywww.praxismedicines.com

Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.

CEO
Marcio Silva De'Souza
IPO
2020
Employees
116
HQ
Boston, MA, US

Price Chart

+745.37% · this period
$347.55$191.83$36.10May 20Nov 18May 20

Valuation

Market Cap
$7.10B
P/E
-29.69
P/S
0.00
P/B
6.88
EV/EBITDA
-18.59
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-43.02%
ROIC
-25.32%

Growth & Income

Revenue
$0 · -100.00%
Net Income
$-303,268,000 · -65.88%
EPS
$-13.48 · -32.03%
Op Income
$-326,198,000
FCF YoY
-89.08%

Performance & Tape

52W High
$358.76
52W Low
$35.21
50D MA
$319.87
200D MA
$219.43
Beta
2.78
Avg Volume
406.47K

Get TickerSpark's AI analysis on PRAX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 14, 26Mastrocola Laurenother127
May 14, 26Nemiroff Alexother78
May 14, 26Kelly Timothy Edwinother121
May 14, 26Sniecinski Meganother89
May 14, 26Souza Marcioother126
Feb 6, 26Arbuckle Stuart Aother478
Feb 6, 26Arbuckle Stuart Aother688
Feb 6, 26Arbuckle Stuart Aother224
Feb 6, 26KINDLER JEFFREY Bother478
Feb 6, 26KINDLER JEFFREY Bother688

Our PRAX Coverage

We haven't published any research on PRAX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate PRAX Report →

Similar Companies